INmune Bio Announces First Patient Dosed in a Phase 1/2 Study of INKmune(TM) in Patients with Metastatic Castration-Resistant Prostate Cancer
Stock Information for INmune Bio Inc.
Loading
Please wait while we load your information from QuoteMedia.